Ipilimumab: A guide to its use in advanced melanoma

American Journal of Clinical Dermatology

Volumn 13, Issue 5, 2012, Pages 349-354

  Lyseng Williamson, Katherine A ^a   Sanford, Mark ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Clinical Q and A; Ipilimumab; Malignant melanoma

Indexed keywords

ALPHA2B INTERFERON; CANCER VACCINE; CORTICOSTEROID; DACARBAZINE; GLYCOPROTEIN GP 100; GP100 PEPTIDE VACCINE; INTERLEUKIN 2; IPILIMUMAB; NITROSOUREA DERIVATIVE; PLATINUM DERIVATIVE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINCA ALKALOID;

ADVANCED CANCER; ADVANCED MELANOMA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; COLITIS; COMPARATIVE STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; ENDOCRINE DISEASE; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNOTOXICITY; INJECTION SITE REACTION; LEUKOCYTOSIS; LIVER TOXICITY; MELANOMA; METASTASIS; NEUROTOXICITY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; REGULATORY T LYMPHOCYTE; SKIN TOXICITY; T LYMPHOCYTE ACTIVATION; VITILIGO;

ANTIBODIES, MONOCLONAL; GP100 MELANOMA ANTIGEN; HUMANS; IMMUNOLOGIC FACTORS; MELANOMA; SKIN NEOPLASMS; VACCINES;

EID: 84864624269     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11209100-000000000-00000     Document Type: Article

References (20)

1. GLOBOCAN 2008: Cancer incidence and mortality worldwide. Lyon: International Agency for Research on Cancer, 2010
2. Marsden JR, Newton-Bishop JA, Burrows L, et al. Revised UK guidelines for the management of cutaneous melanoma 2010. Br J Dermatol 2010 Aug; 163 (2): 238-56
3. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: An overview. Oncology (Williston) 2009 May; 23 (6): 488-96
4. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995; 181: 193-201
5. Yervoy (ipilimumab) injection for infusion: Prescribing information. Princeton (NJ): Bristol-Myers Squibb Co., 2011 Mar
6. Yervoy 5mg/ml concentrate for solution for infusion: Summary of product characteristics. London: European Medicines gency, 2011 Jul 25
7. Agarwala SS. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: Cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma. Melanoma Res 2010 Feb; 20 (1): 1-10
8. Hodi FS, Butler M, Obel DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008 Feb 26; 105 (8): 3005-10
9. Lorigan P, Sosman JA, Haanen JB, et al. Clinical response to ipilimumab: Effect of systemic corticosteroids used to manage immune-related adverse events (irAEs) [abstract no. 1331P]. Ann Oncol 2010 Oct; 21 Suppl. 8: Viii404
10. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma [published erratum appears in N Engl J Med 2010 Sep 23; 363 (13): 1290]. N Engl J Med 2010 Aug 19; 363 (8): 711-23
11. Haanen JB, Hodi FS, O'Day SJ, et al. Ipilimumab improves overall survival in patients with previously treated, advanced melanoma: Long-term survival results from a phase III trial [abstract no. 1327P]. Ann Oncol 2010 Oct; 21 Suppl. 8: Viii402. Plus poster presented at the 35th European Society for Medical Oncology Conference; 2010 Oct 8-12; Milan
12. Robert C, Hodi FS, O'Day SJ, et al. Re-induction with ipilimumab, GP100 peptide vaccine, or a combination of both in a phase III study of previouslytreated patients with advanced melanoma: Update of clinical characteristics of patients [abstract no. 1330P]. Ann Oncol 2010 Oct; 21 Suppl. 8: Viii403
13. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011 Jun 30; 364 (26): 2517-26
14. Kaehler KC, Piel S, Livingstone E, et al. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: Identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol 2010 Oct; 37 (5): 485-98
15. O'Day S, Weber JS, Wolchok JD, et al. Effectiveness of treatment guidance on diarrhea and colitis across ipilimumab studies [abstract no. 8554]. J Clin Oncol 2011 May 20; 29 (15 Suppl.
16. Ibrahim RA, Berman DM, DePril V, et al. Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma [abstract no. 8583]. J Clin Oncol 2011 May 20; 29 (15 Suppl.
17. Blesa JMG, Pulido EG, Candel VA, et al. Melanoma: From darkness to promise. Am J Clin Oncol 2011 Apr; 34 (2): 179-87
18. Eastern Cooperative Oncology Group. Ipilimumab or high-dose interferon alfa-2b in treating patients with high-risk stage III or stage IV melanoma that has been removed by surgery [ClinicalTrials.gov identifier NCT01274338]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2012 Apr 18]
19. Bristol-Meyers Squibb. Efficacy study of ipilimumab versus placebo to prevent recurrence after complete resection of high risk stage III melanoma [ClinicalTrials. gov identifier NCT00636168]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2012 Apr 18]
20. Sanford M. Ipilimumab in previously treated patients with advanced melanoma. Biodrugs 2012; 26 (3): 185-93